Ani Pharmaceuticals(NASDAQ) ANIP

ANI makes medicine for people with rare or common health issues. It develops and sells both branded and cheaper generic drugs. The company runs factories and sells products across the world.

What ANI Brings to Patients

• Rare Disease: Specialty drugs such as Cortrophin Gel for autoimmune issues and treatments for chronic eye conditions.
• Generics: Portfolio of over 120 products covering hormones, oncology, and other therapeutic areas.
• Branded Products: Established prescription medicines including treatments for high blood pressure and various infections.
• Manufacturing Services: Contract development and production services for other pharmaceutical firms at company-owned sites.

Strategic Steps to Grow

• Acquired Alimera Sciences in September 2024 to enter the ophthalmology market and expand into Europe.
• Purchased Novitium Pharma in 2021 to increase manufacturing capacity and research for generic drugs.
• Released a prefilled syringe for Cortrophin Gel in 2025 to simplify how patients take their medicine.

Operations and Global Reach

ANI operates three specialized factories in Minnesota and New Jersey that handle complex formats like liquids and controlled substances. Its distribution network connects with major wholesalers, specialty pharmacies, and international partners in Europe and Asia.

The Recent Financial Scorecard

• Revenue was $247.1 million in Q4 2025, up 29.6% year-over-year.
• Net income turned positive at $27.5 million in Q4 2025, improved 367.5% from a loss in Q4 2024.
• Operating cash flow reached $30.4 million in Q4 2025, up 91.5% from the previous year.
• Market cap grew to $1.6 billion in Q4 2025, up 47.3% from Q4 2024.

Bottom Line

ANI has transitioned from a generic drug manufacturer to a diversified firm with a primary focus on high-value rare disease treatments. Its strategy combines specialized internal manufacturing with targeted acquisitions to expand its international footprint.